288 related articles for article (PubMed ID: 26881476)
21. Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives.
Xie Z; Meng Z; Yang X; Duan Y; Wang Q; Liao C
J Med Chem; 2023 Apr; 66(8):5332-5363. PubMed ID: 37037122
[TBL] [Abstract][Full Text] [Related]
22. Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.
Ely LK; Lolicato M; David T; Lowe K; Kim YC; Samuel D; Bessette P; Garcia JL; Mikita T; Minor DL; Coughlin SR
Structure; 2018 Feb; 26(2):187-198.e4. PubMed ID: 29336885
[TBL] [Abstract][Full Text] [Related]
23. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.
Al-Horani RA; Ponnusamy P; Mehta AY; Gailani D; Desai UR
J Med Chem; 2013 Feb; 56(3):867-78. PubMed ID: 23316863
[TBL] [Abstract][Full Text] [Related]
24. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.
Schaefer M; Buchmueller A; Dittmer F; Straßburger J; Wilmen A
J Mol Biol; 2019 Dec; 431(24):4817-4833. PubMed ID: 31655039
[TBL] [Abstract][Full Text] [Related]
25. Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.
Carle V; Wu Y; Mukherjee R; Kong XD; Rogg C; Laurent Q; Cecere E; Villequey C; Konakalla MS; Maric T; Lamers C; Díaz-Perlas C; Butler K; Goto J; Stegmayr B; Heinis C
J Med Chem; 2021 May; 64(10):6802-6813. PubMed ID: 33974422
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor.
Obaidullah AJ; Al-Horani RA
Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):40-48. PubMed ID: 28552062
[TBL] [Abstract][Full Text] [Related]
27. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
Salomon O; Gailani D
J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
[TBL] [Abstract][Full Text] [Related]
28. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.
Corte JR; Fang T; Pinto DJ; Orwat MJ; Rendina AR; Luettgen JM; Rossi KA; Wei A; Ramamurthy V; Myers JE; Sheriff S; Narayanan R; Harper TW; Zheng JJ; Li YX; Seiffert DA; Wexler RR; Quan ML
Bioorg Med Chem; 2016 May; 24(10):2257-72. PubMed ID: 27073051
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Factor XIa Reduces the Frequency of Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.
Wang X; Kurowski S; Wu W; Castriota GA; Zhou X; Chu L; Ellsworth KP; Chu D; Edmondson S; Ali A; Andre P; Seiffert D; Erion M; Gutstein DE; Chen Z
J Pharmacol Exp Ther; 2017 Mar; 360(3):476-483. PubMed ID: 28035007
[TBL] [Abstract][Full Text] [Related]
30. Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis.
David T; Kim YC; Ely LK; Rondon I; Gao H; O'Brien P; Bolt MW; Coyle AJ; Garcia JL; Flounders EA; Mikita T; Coughlin SR
Sci Transl Med; 2016 Aug; 8(353):353ra112. PubMed ID: 27559095
[TBL] [Abstract][Full Text] [Related]
31. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides.
Al-Horani RA; Desai UR
J Med Chem; 2014 Jun; 57(11):4805-18. PubMed ID: 24844380
[TBL] [Abstract][Full Text] [Related]
32. Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa/tissue factor from the blood-feeding nematode Ancylostoma caninum.
Li D; He Q; Kang T; Yin H; Jin X; Li H; Gan W; Yang C; Hu J; Wu Y; Peng L
Biochem Biophys Res Commun; 2010 Feb; 392(2):155-9. PubMed ID: 20059979
[TBL] [Abstract][Full Text] [Related]
33. Generation and characterization of aptamers targeting factor XIa.
Woodruff RS; Ivanov I; Verhamme IM; Sun MF; Gailani D; Sullenger BA
Thromb Res; 2017 Aug; 156():134-141. PubMed ID: 28644959
[TBL] [Abstract][Full Text] [Related]
34. Factor XIa Inhibitors as New Anticoagulants.
Quan ML; Pinto DJP; Smallheer JM; Ewing WR; Rossi KA; Luettgen JM; Seiffert DA; Wexler RR
J Med Chem; 2018 Sep; 61(17):7425-7447. PubMed ID: 29775297
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
[TBL] [Abstract][Full Text] [Related]
36. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors.
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
J Med Vasc; 2023 Apr; 48(2):69-80. PubMed ID: 37422330
[TBL] [Abstract][Full Text] [Related]
37. The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.
Wu W; Li H; Navaneetham D; Reichenbach ZW; Tuma RF; Walsh PN
Blood; 2012 Jul; 120(3):671-7. PubMed ID: 22674803
[TBL] [Abstract][Full Text] [Related]
38. Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation.
Parunov LA; Liang Y; Lu Q; Shibeko AM; Tucker EI; Lee TK; Ataullakhanov FI; Scott DE; Ovanesov MV
Blood Adv; 2023 Jun; 7(11):2622-2631. PubMed ID: 36724509
[TBL] [Abstract][Full Text] [Related]
39. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
[TBL] [Abstract][Full Text] [Related]
40. Factor IX(a) inhibitors: an updated patent review (2003-present).
Afosah DK; Ofori E; Mottamal M; Al-Horani RA
Expert Opin Ther Pat; 2022 Apr; 32(4):381-400. PubMed ID: 34991418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
